Last edition
News about "antibody therapy "
US FDA Grants AbbVie's Telisotuzumab 2 Breakthrough Designations
The US FDA has granted AbbVie’s Temab-A 2 Breakthrough Therapy Designations (BTDs) for CRC and NSCLC, advancing its c-Met-directed ADC development in solid tumors.
Antibody Therapy | 08/10/2026 | By News Bureau | 241
VectorY Doses First Patient in Phase I/II PIONEER-ALS Trial of TDP-43 Targeting Therapy VTx-002
VectorY initiates clinical evaluation of VTx-002, a first-in-class vectorised antibody therapy targeting TDP-43 pathology in ALS, with first patient dosed at Mass General Brigham.
Antibody Therapy | 11/02/2026 | By News Bureau | 271
ADEL Signs USD 1.04 Billion Global Licensing Deal with Sanofi for Alzheimer's Drug
ADEL has signed a global licensing deal with Sanofi for its investigational Alzheimer’s therapy ADEL-Y01, valued at up to USD 1.04 billion, including a USD 80 million upfront payment, milestone payments and royalties.
Antibody Therapy | 16/12/2025 | By News Bureau | 237
Danish drugmaker Novo Nordisk has entered into a definitive asset purchase and license agreement with US-based Omeros Corporation for zaltenibart (formerly OMS906), a clinical-stage antibody therapy being developed for rare blood and kidney disorders.
Antibody Therapy | 16/10/2025 | By Dineshwori | 368
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy